Trending

Fasenra

Sanofi/Regeneron on notice as FDA reviews GSK’s Nucala for nasal polyps

Sanofi/Regeneron on notice as FDA reviews GSK’s Nucala for nasal polyps

Sanofi and Regeneron’s Dupixent has had the US market for the treatment of chronic rhinosinusitis with nasal polyps

X

Sanofi/Regeneron on notice as FDA reviews GSK’s Nucala for nasal polyps

https://pharmaphorum.com/news/dupixent-on-notice-as-fda-reviews-gsks-nucala-for-nasal-polyps/

EU clears GSK’s asthma drug Nucala in patient-friendly format

EU clears GSK’s asthma drug Nucala in patient-friendly format

With competition heating up in the severe asthma category, GlaxoSmithKline has a new EU approval that it hopes

X

EU clears GSK’s asthma drug Nucala in patient-friendly format

https://pharmaphorum.com/news/eu-clears-gsks-asthma-drug-nucala-in-patient-friendly-format/

NICE broadens approval for AstraZeneca’s severe asthma drug

NICE broadens approval for AstraZeneca’s severe asthma drug

AstraZeneca’s Fasenra (benralizumab) has seen its fortunes reverse after NICE approved the drug for severe eosinophilic asthma –

X

NICE broadens approval for AstraZeneca’s severe asthma drug

https://pharmaphorum.com/news/nice-broadens-approval-for-astrazenecas-severe-asthma-drug/

AstraZeneca’s respiratory biologic fails again in COPD

AstraZeneca’s respiratory biologic fails again in COPD

AstraZeneca (AZ) and MedImmune, have announced that the latest trial of Fasenra (benralizumab) in patients with moderate-to-very-severe chronic obstructive pulmonary disease (COPD) did not provide a statistically-significant reduction in exacerbations.

X

AstraZeneca’s respiratory biologic fails again in COPD

https://pharmaphorum.com/news/astrazenecas-respiratory-biologic-copd/

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com